8-K: Aadi Bioscience Halts PRECISION1 Trial, Cuts Workforce and R&D to Extend Cash Runway

Aadi Bioscience is halting its PRECISION1 trial due to efficacy concerns, reducing its workforce by 32% and R&D staff by 80%, and pausing enrollment in other trials to extend its cash runway into the second half of 2026.

Summary

• Aadi Bioscience has decided to halt the PRECISION1 trial of nab-sirolimus as it is unlikely to meet the efficacy threshold for accelerated approval.
• The company will reduce its workforce by 22 employees, which is approximately 32% of its total workforce.
• This workforce reduction is expected to incur non-recurring charges of $2.2 to $2.5 million, primarily for severance payments and benefits.
• The majority of these charges are expected to be incurred in the third quarter of 2024, with implementation completed by the end of the fourth quarter of 2024.
• Aadi will also reduce its R&D headcount by 80% and pause new enrollment in two other Phase 2 trials.
• These actions are aimed at preserving cash and extending the company's cash runway into at least the second half of 2026.
• The company will focus on its commercial business for FYARRO, which had sales of $6.2 million in the second quarter of 2024.
• A strategic review is being conducted to maximize shareholder value.

Sentiment

Score: 3

Explanation: The document indicates significant negative developments including a failed trial, major workforce reductions, and a strategic review, suggesting a challenging period for the company. While the focus on FYARRO and cash preservation are positive, the overall tone is negative.

Positives

• The company is taking decisive action to preserve cash and extend its runway into at least the second half of 2026.
• Aadi is focusing on its commercial business for FYARRO, which has shown promising sales.
• The company is conducting a strategic review to maximize shareholder value.
• Patients benefiting from the PRECISION1 trial will be transitioned to an expanded access protocol.
• The company has enrolled sufficient patients in the EEC and NETs trials to assess initial efficacy signals later this year.

Negatives

• The PRECISION1 trial was halted due to insufficient efficacy, which was a key goal of the Phase 2 study.
• A significant workforce reduction of 32% will impact 22 employees.
• The company is incurring non-recurring charges of $2.2 to $2.5 million due to the workforce reduction.
• There is a significant reduction in R&D headcount by 80%.
• New enrollment is paused in two other Phase 2 trials.

Risks

• The company's actual results may differ from estimates regarding severance costs and timing of the workforce reduction.
• There is a risk that the company may incur additional costs not currently contemplated.
• The company faces risks associated with the commercialization of FYARRO.
• There are risks of unforeseen adverse reactions or side effects during the commercialization and development of FYARRO.
• The company faces uncertainties associated with the clinical development and regulatory approval of FYARRO in additional indications.
• There is a risk of failure to demonstrate the efficacy of FYARRO in clinical trials for additional indications.
• The company faces risks related to its estimates regarding future expenses, capital requirements, and the need for additional financing.

Future Outlook

Aadi Bioscience aims to extend its cash runway into at least the second half of 2026 by reducing workforce and R&D expenses, while focusing on the commercialization of FYARRO and conducting a strategic review to maximize shareholder value. The company will also provide a complete analysis of the PRECISION1 trial at a later date and assess initial efficacy signals from the EEC and NETs trials later this year.

Management Comments

• David Lennon, President and CEO of Aadi Bioscience, stated that the PRECISION1 trial fell short of delivering what they believe would be required to support an accelerated approval.
• He also thanked the dedicated Aadi employees who worked on the trial and are negatively impacted by the outcome.
• Management has taken necessary steps to immediately preserve cash runway and hired an advisory firm to explore all options to maximize value for shareholders.

Industry Context

The decision to halt the PRECISION1 trial and reduce R&D spending reflects the challenges in developing new cancer therapies and the need for companies to manage resources effectively. The focus on commercializing existing products like FYARRO is a common strategy for biotech companies facing clinical trial setbacks. The strategic review suggests the company is exploring various options, including potential partnerships or acquisitions, which is not uncommon in the biotech industry.

Comparison to Industry Standards

• The halting of a Phase 2 trial due to efficacy concerns is not uncommon in the pharmaceutical industry, where clinical trial success rates are often low.
• The workforce reduction of 32% and R&D headcount reduction of 80% are significant and indicate a major shift in the company's strategy, which is more aggressive than some companies but not unheard of in the face of clinical trial setbacks.
• The focus on commercializing an existing product, FYARRO, is a common strategy for companies that have experienced clinical trial failures, similar to how companies like Clovis Oncology focused on Rubraca after setbacks with other pipeline candidates.
• The strategic review to maximize shareholder value is a standard response when a company faces significant challenges, similar to how companies like Tesaro explored strategic alternatives after clinical trial disappointments.
• The cash runway extension into 2H 2026 is a positive step, but the company will need to demonstrate strong commercial performance with FYARRO to maintain investor confidence, similar to how companies like Exelixis have relied on their commercial products after pipeline setbacks.

Stakeholder Impact

• Shareholders will be impacted by the halting of the PRECISION1 trial and the strategic review.
• Employees will be impacted by the workforce reduction of 32% and the R&D headcount reduction of 80%.
• Patients who were benefiting from the PRECISION1 trial will be transitioned to an expanded access protocol.
• The company's focus on FYARRO may impact patients with PEComa.

Next Steps

• The company will transition patients benefiting from the PRECISION1 trial to an expanded access protocol.
• A complete analysis of the PRECISION1 trial will be provided at a later date.
• The company will assess initial efficacy signals from the EEC and NETs trials later this year.
• A strategic review will be conducted to maximize shareholder value.

Key Dates

Keywords

Aadi Bioscience, FYARRO, PRECISION1 trial, workforce reduction, R&D, cash runway, nab-sirolimus, PEComa, strategic review, clinical trials, severance, TSC1, TSC2